Related Experiment Video
Updated: Jun 1, 2025
12:32
High-resolution Respirometry to Measure Mitochondrial Function of Intact Beta Cells in the Presence of Natural Compounds
Published on: January 23, 2018
12.0K
Investigating GLP-1 Injections: Potential Mitochondrial Dysfunction in Non-Diabetic Patients Presenting with
Jana Jamail1, Rachel Knowles2, Leslie Fuller3
1Certified Nutritional Consultant, Certified Plant-Based Nutrition, Certified Wellness Counseling. Human Nutrition and Functional Medicine Masters Alumnus, University of Western States, CEO and Founder of Rose+Ginger Nutrition, Austin, Texas, USA.
Integrative Medicine (Encinitas, Calif.)
|January 20, 2025
Summary
Glucagon-like peptide-1 (GLP-1) medications may cause mitochondrial dysfunction side effects in non-diabetic patients. Nutritional and supplemental interventions successfully managed hypoglycemia and migraines in one case study.
Area of Science:
- Endocrinology
- Metabolic Research
- Neuroscience
Background:
- Glucagon-like peptide-1 (GLP-1) receptor agonists are frequently prescribed for weight management in individuals with and without type 2 diabetes.
- Limited data exists on the impact of GLP-1 medications on mitochondrial function, especially in non-diabetic populations.
Observation:
- A 43-year-old female with a BMI of 32 experienced hypoglycemia and persistent migraines with auras following treatment with Ozempic and Mounjaro.
- The patient's symptoms emerged after initiating GLP-1 medication therapy.
Findings:
- Dietary modifications, including increased protein intake and frequent small meals, helped stabilize blood sugar levels.
- Supplementation with CoQ10, D-ribose, vitamin B complex, and acetyl-L-carnitine improved mitochondrial function and resolved migraine symptoms.
- The patient's blood sugar normalized, and her migraines ceased after implementing these interventions.
Implications:
- This case highlights the potential for GLP-1 medications to induce mitochondrial dysfunction and associated side effects in non-diabetic individuals.
- Nutritional and supplemental strategies may effectively mitigate these adverse effects.
- Further research is warranted to elucidate the mechanisms underlying GLP-1-induced mitochondrial changes and to develop targeted interventions.
Related Concept Videos
01:15Hypoglycemia and Glucagon
150
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
150
01:24Glucagon-like Receptor Agonists
295
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
295
01:23Dipeptidyl Peptidase 4 Inhibitors
165
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
165
01:06Oral Hypoglycemic Agents: Glinides
136
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
136
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
165
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
165
01:22Diabetes Mellitus: Type 2 and Gestational
2.2K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.2K